Goldman Sachs’s X4 Pharmaceuticals XFOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.28M | Buy |
916,536
+34,402
| +4% | +$141K | ﹤0.01% | 4019 |
|
|
2026
Q1 | $3.64M | Buy |
882,134
+50,244
| +6% | +$188K | ﹤0.01% | 3999 |
|
|
2025
Q4 | $3.33M | Buy |
+831,890
| New | +$3.02M | ﹤0.01% | 4129 |
|
|
2025
Q3 | – | Sell |
-18,864
| Closed | -$35.8K | – | 6684 |
|
|
2025
Q2 | $35.8K | Buy |
18,864
+9,735
| +107% | +$39.8K | ﹤0.01% | 5944 |
|
|
2025
Q1 | $64.7K | Sell |
9,129
-6,792
| -43% | -$93.5K | ﹤0.01% | 5850 |
|
|
2024
Q4 | $350K | Buy |
15,921
+6,168
| +63% | +$98.3K | ﹤0.01% | 5428 |
|
|
2024
Q3 | $196K | Buy |
9,753
+4,047
| +71% | +$84.5K | ﹤0.01% | 5466 |
|
|
2024
Q2 | $99.3K | Sell |
5,706
-29,592
| -84% | -$968K | ﹤0.01% | 5404 |
|
|
2024
Q1 | $1.47M | Buy |
35,298
+32,872
| +1,355% | +$915K | ﹤0.01% | 4075 |
|
|
2023
Q4 | $61K | Buy |
2,426
+773
| +47% | +$18.8K | ﹤0.01% | 5356 |
|
|
2023
Q3 | $54.1K | Sell |
1,653
-9,495
| -85% | -$414K | ﹤0.01% | 5271 |
|
|
2023
Q2 | $649K | Buy |
11,148
+8,365
| +301% | +$430K | ﹤0.01% | 4598 |
|
|
2023
Q1 | $72.6K | Buy |
2,783
+950
| +52% | +$27.9K | ﹤0.01% | 5498 |
|
|
2022
Q4 | $54.6K | Sell |
1,833
-13
| -0.7% | -$616 | ﹤0.01% | 5584 |
|
|
2022
Q3 | $95K | Buy |
+1,846
| New | +$63.8K | ﹤0.01% | 5698 |
|
|
2022
Q1 | – | Sell |
-698
| Closed | -$48K | – | 6941 |
|
|
2021
Q4 | $48K | Buy |
698
+349
| +100% | +$44.1K | ﹤0.01% | 6275 |
|
|
2021
Q3 | $55K | Sell |
349
-1,451
| -81% | -$239K | ﹤0.01% | 6028 |
|
|
2021
Q2 | $351K | Sell |
1,800
-968
| -35% | -$243K | ﹤0.01% | 5430 |
|
|
2021
Q1 | $715K | Buy |
2,768
+901
| +48% | +$237K | ﹤0.01% | 4862 |
|
|
2020
Q4 | $360K | Buy |
1,867
+153
| +9% | +$30.1K | ﹤0.01% | 4796 |
|
|
2020
Q3 | $348K | Buy |
1,714
+661
| +63% | +$158K | ﹤0.01% | 4660 |
|
|
2020
Q2 | $294K | Buy |
1,053
+581
| +123% | +$159K | ﹤0.01% | 4638 |
|
|
2020
Q1 | $142K | Sell |
472
-166
| -26% | -$47.1K | ﹤0.01% | 4842 |
|
|
2019
Q4 | $205K | Buy |
638
+143
| +29% | +$51.3K | ﹤0.01% | 4886 |
|
|
2019
Q3 | $189K | Sell |
495
-573
| -54% | -$227K | ﹤0.01% | 4839 |
|
|
2019
Q2 | $480K | Buy |
+1,068
| New | +$543K | ﹤0.01% | 4419 |
|
|
2019
Q1 | – | Sell |
-130
| Closed | -$54K | – | 5494 |
|
|
2018
Q4 | $54K | Buy |
+130
| New | +$49.6K | ﹤0.01% | 5085 |
|
Other funds holding XFOR
BCLSI
PA
SVCM
EAM
DTC
KCM
Goldman Sachs's XFOR Position: Q2 2026 in Review
Goldman Sachs increased its X4 Pharmaceuticals (XFOR) stake by 3.9% in Q2 2026, buying an estimated $141K and bringing the position to 916,536 shares worth $4.28M. The position accounts for ﹤0.01% of the portfolio, ranked #4019.
Goldman Sachs first reported a position in XFOR in Q4 2018 and has held it in 27 quarters since. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.
- Goldman Sachs held 916,536 shares of X4 Pharmaceuticals worth $4.28M as of Q2 2026.
- Goldman Sachs bought 34,402 X4 Pharmaceuticals shares in Q2 2026, an estimated $141K.
- X4 Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4019 holding.
- Goldman Sachs first reported a position in X4 Pharmaceuticals in Q4 2018 and has held it in 27 quarters since.
- 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.